Jefferies initiated coverage of BioAge Labs (BIOA) with a Buy rating and $42 price target BioAge is a clinical stage biotech focusing on metabolic diseases, the analyst tells investors in a research note. The firm says the company’s lead drug Azelaprag has a differentiated mechanism of action as exercise mimetic for obesity.